AstraZeneca stroke drug fails in pivotal trial
(Reuter
Reuters - AstraZeneca Plc said on Thursday its
experimental stroke drug NXY-059 failed to meet its goal in a
pivotal Phase III clinical trial, dealing a fresh blow to its
already depleted new product pipeline.
Stumble It!
Tweet This
Bookmark on Delicious
Share on Facebook
Share on MySpace